Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 3, 2016, Pages 625-634

  Wyllie, Susan ^a   Foth, Bernardo J ^b,c   Kelner, Anna ^a   Sokolova, Antoaneta Y ^a   Berriman, Matthew ^b   Fairlamb, Alan H ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c Sophia Genetics SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FEXINIDAZOLE; NIFURTIMOX; NITROREDUCTASE; OXIDOREDUCTASE; ANTIPROTOZOAL AGENT; AROMATIC NADH-DEPENDENT NITROREDUCTASE; NITROIMIDAZOLE DERIVATIVE;

AFRICAN TRYPANOSOMIASIS; ALLELE; ARTICLE; CHROMOSOME 7; CLONE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACTIVATION; DRUG MECHANISM; DRUG SENSITIVITY; GENE INACTIVATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENOME; HEMIZYGOSITY; NONHUMAN; PHENOTYPE; TRYPANOSOMA BRUCEI; DNA SEQUENCE; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM; TRYPANOSOMA BRUCEI BRUCEI;

ANTIPROTOZOAL AGENTS; DRUG RESISTANCE; GENOME, PROTOZOAN; NIFURTIMOX; NITROIMIDAZOLES; NITROREDUCTASES; PARASITIC SENSITIVITY TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; TRYPANOSOMA BRUCEI BRUCEI;

EID: 84960830500     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv376     Document Type: Article

References (27)

1. Priotto G, Kasparian S, Mutombo Wet al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 2009; 374: 56-64.
2. Jennings FW, Urquhart GM. The use of the 2 substituted 5-nitroimidazole, fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice. Z Parasitenkd 1983; 69: 577-81.
3. Wyllie S, Patterson S, Stojanovski L et al. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Sci Transl Med 2012; 4: 119re1.
4. Gupta S, Yardley V, Vishwakarma P et al. Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis. J Antimicrob Chemother 2015; 70: 518-27.
5. Trochine A, Creek DJ, Faral-Tello P et al. Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics. PLoS Negl Trop Dis 2014; 8: e2844.
6. Hall BS, Wilkinson SR. Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrob Agents Chemother 2012; 56: 115-23.
7. Hall BS, Bot C, Wilkinson SR. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J Biol Chem 2011; 286: 13088-95.
8. Wilkinson SR, Taylor MC, Horn D et al. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci USA 2008; 105: 5022-7.
9. Sokolova AY, Wyllie S, Patterson S et al. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrob Agents Chemother 2010; 54: 2893-900.
10. Mejia AM, Hall BS, Taylor MC et al. Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population. J Infect Dis 2012; 206: 220-8.
11. Wyllie S, Patterson S, Fairlamb AH. Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation. Antimicrob Agents Chemother 2013; 57: 901-6.
12. Greig N, Wyllie S, Patterson S et al. A comparative study of methylglyoxal metabolism in trypanosomatids. FEBS J 2009; 276: 376-86.
13. Jones DC, Hallyburton I, Stojanovski L et al. Identification of a k-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis. Biochem Pharmacol 2010; 80: 1478-86.
14. Martin K, Smith TK. The myo-inositol-1-phosphate synthase gene is essential in Trypanosoma brucei. Biochem Soc Trans 2005; 33: 983-5.
15. Wirtz E, Leal S, Ochatt C et al. A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in Trypanosoma brucei. Mol Biochem Parasitol 1999; 99: 89-101.
16. Kozarewa I, Ning ZM, Quail MA et al. Amplification-free Illumina sequencing-library preparation facilitates improved mapping and assembly of (G+C)-biased genomes. Nat Methods 2009; 6: 291-5.
17. Berriman M, Ghedin E, Hertz-Fowler C et al. The genome of the African trypanosome Trypanosoma brucei. Science 2005; 309: 416-22.
18. Li H, Handsaker B, Wysoker A et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078-9.
19. Acestor N, Zikova A, Dalley RA et al. Trypanosoma brucei mitochondrial respiratome: composition and organization in procyclic form. Mol Cell Proteomics 2011; 10: M110.
20. Alsford S, Eckert S, Baker N et al. High-throughput decoding of antitrypanosomal drug efficacy and resistance. Nature 2012; 482: 232-6.
21. Siegel TN, Hekstra DR, Kemp LE et al. Four histone variants mark the boundaries of polycistronic transcription units in Trypanosoma brucei. Genes Dev 2009; 23: 1063-76.
22. Callejas S, Leech V, Reitter C et al. Hemizygous subtelomeres of an African trypanosome chromosome may account for over 75% of chromosome length. Genome Res 2006; 16: 1109-18.
23. Vincent IM, Creek D, Watson DG et al. A molecular mechanism for eflornithine resistance in African trypanosomes. PLoS Pathog 2010; 6: e1001204.
24. Obado SO, Taylor MC, Wilkinson SR et al. Functional mapping of a trypanosome centromere by chromosome fragmentation identifies a 16-kb GC-rich transcriptional 'strand-switch' domain as a major feature. Genome Res 2005; 15: 36-43.
25. Sokolova AY. Nitroaromatic pro-drug activation and resistance in the African trypanosome. PhD Thesis. University of Dundee, 2011.
26. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19: 111-26.
27. Patterson S, Wyllie S. Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects. Trends Parasitol 2014; 30: 289-98.